1. Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer 
Pamela Samson, MD, MPHS, Traves D. Crabtree, MD, Cliff G. Robinson, MD, Daniel Morgensztern, MD, Stephen Broderick, MD, A. Sasha Krupnick, MD, Daniel Kreisel, MD, PhD, G. Alexander Patterson, MD, Bryan Meyers, MD, MPH, Varun Puri, MD, MSCI 
The Annals of Thoracic Surgery 
Volume 103, Issue 4, Pages (April 2017)
DOI: /j.athoracsur
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Histogram of clinical stage IIIA NSCLC patients in the NCDB from 2006 to 2012, by length of time between start of induction therapy and date of surgical resection.StartYear 1Year 2Year 3Year 4Year 5Early surgery Delayed surgery1,5291,
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Kaplan-Meier analysis for clinical stage IIIA non-small cell lung cancer patients, by early versus delayed interval from the start of induction therapy to date of surgery.StartYear 1Year 2Year 3Year 4Early surgery Delayed surgery
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Kaplan-Meier analysis for clinical stage IIIA non-small cell lung cancer patients with positive surgical margins (≥R1), by early versus delayed interval from the start of induction therapy to date of surgery.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions